TXMD TherapeuticsMD, Inc.

Overview and Growth

TherapeuticsMD, Inc. generated $3.02M of revenue in fiscal 2025, with net loss of $569.00K and an operating cash inflow of $2.45M. At $3.02M, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Compared with $1.76M in fiscal 2024, revenue recorded a 71.6% year-over-year increase. Diluted earnings per share were -$0.05, translating the period’s attributable earnings into the amount reported for each diluted share. A diluted share base of 11.57M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. The diluted share count was 0.3% higher than fiscal 2024, when diluted shares averaged 11.53M, adding context to the EPS comparison. At period end, total assets were $37.66M, framing the scale of the company’s operating and financing commitments. Asset turnover was 0.08x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

The reported operating result was an operating loss of $4.39M, reflecting costs that exceeded gross profit. The operating loss equaled 145.3% of revenue, showing the scale of the operating deficit relative to sales. After all below-operating-line items, the company recorded a net loss of $569.00K for the fiscal year. The net loss equaled 18.8% of revenue, showing the bottom-line deficit relative to the company’s sales base. EBITDA was negative $4.01M, showing a deficit before interest, taxes, depreciation, and amortization. Before income taxes, the company recorded a loss of $653.00K, bridging the operating result to the final net loss. The pretax loss equaled 21.6% of revenue, measuring the pre-tax deficit against sales. The net loss equaled 2.1% of period-end equity, showing the deficit relative to book capital. The loss-to-assets relationship was 1.5%, placing the bottom-line deficit against the company’s resource base. The bottom-line deficit decreased from $2.18M in fiscal 2024 to $569.00K.

Liquidity and Capital Structure

Total assets were $37.66M, supported by $10.78M of liabilities and $26.88M of shareholder equity. Current assets were $14.45M against $4.79M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 3.02x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. The company held $7.48M in cash and equivalents, a narrower liquidity measure than total current assets. Measured only with cash and equivalents, coverage of current liabilities was 156.4%, excluding receivables and other current assets. Book equity represented 71.4% of total assets, quantifying the balance-sheet share supported by shareholder capital. Liabilities represented 28.6% of total assets, quantifying the liability-funded share of the company’s resource base. The cash-to-assets relationship was 19.9%, comparing reported cash and equivalents with the full positive asset balance. Compared with $38.82M in fiscal 2024, the current asset base moved 3.0% and finished lower. Book equity was 1.8% lower than fiscal 2024 equity of $27.37M, showing how shareholder capital changed year over year. Cash and equivalents were 47.9% higher than fiscal 2024 cash of $5.06M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

Operating activities produced a cash inflow of $2.45M, giving the cash-flow counterpart to the accrual-based profit measures reported for the year. Operating cash flow of $2.45M finished above fiscal 2024 operating cash flow of $1.17M, showing the year-over-year direction of cash generation.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.